
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group Inc. has demonstrated strong revenue growth, reporting $98.6 million in the most recent quarter, which reflects a year-over-year increase of approximately 13%, supported by significant contributions from both its wound portfolio and surgical segments. The company's positive trajectory is further underscored by an upward revision in the 2025 revenue estimate to $387.3 million, up from a previous estimate of $374.0 million, largely attributed to robust second-quarter performance and expanding surgical business capabilities. While selling, general, and administrative expenses rose about 16% year-over-year to $64.2 million, this investment in sales and legal support may enhance future revenue generation potential.
Bears say
MiMedx Group Inc. reported a decline in gross margin to approximately 81% from 83% in the second quarter of 2025, attributed to production variances and an unfavorable product mix. Despite the company's long-term guidance of achieving low double-digit year-over-year revenue growth and an adjusted EBITDA margin above 20%, concerns linger regarding potential negative changes to reimbursement rates from CMS, which could significantly affect its business. Given these factors, the financial outlook for MiMedx Group appears challenging, highlighting risks associated with profitability and revenue sustainability.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares